Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Lowered by Maxim Group

Reviva Pharmaceuticals (NASDAQ:RVPH) was downgraded by Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Marketbeat reports.

RVPH has been the subject of a number of other reports. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, March 14th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and issued a $40.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. Finally, D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $66.67.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ RVPH opened at $0.85 on Wednesday. The firm has a fifty day moving average price of $3.25 and a 200-day moving average price of $7.44. The stock has a market cap of $10.82 million, a PE ratio of -0.09 and a beta of 0.64. Reviva Pharmaceuticals has a 1 year low of $0.59 and a 1 year high of $23.20.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals during the second quarter worth $31,000. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the third quarter worth $37,000. NewEdge Advisors LLC bought a new position in Reviva Pharmaceuticals during the first quarter valued at $58,000. State Street Corp lifted its position in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.